Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.
Harris, P.A., Faucher, N., George, N., Eidam, P.M., King, B.W., White, G.V., Anderson, N.A., Bandyopadhyay, D., Beal, A.M., Beneton, V., Berger, S.B., Campobasso, N., Campos, S., Capriotti, C.A., Cox, J.A., Daugan, A., Donche, F., Fouchet, M.H., Finger, J.N., Geddes, B., Gough, P.J., Grondin, P., Hoffman, B.L., Hoffman, S.J., Hutchinson, S.E., Jeong, J.U., Jigorel, E., Lamoureux, P., Leister, L.K., Lich, J.D., Mahajan, M.K., Meslamani, J., Mosley, J.E., Nagilla, R., Nassau, P.M., Ng, S.L., Ouellette, M.T., Pasikanti, K.K., Potvain, F., Reilly, M.A., Rivera, E.J., Sautet, S., Schaeffer, M.C., Sehon, C.A., Sun, H., Thorpe, J.H., Totoritis, R.D., Ward, P., Wellaway, N., Wisnoski, D.D., Woolven, J.M., Bertin, J., Marquis, R.W.(2019) J Med Chem 62: 5096-5110
- PubMed: 31013427 
- DOI: 10.1021/acs.jmedchem.9b00318
- Primary Citation of Related Structures:  
6OCQ, 6R5F - PubMed Abstract: 
RIP1 kinase regulates necroptosis and inflammation and may play an important role in contributing to a variety of human pathologies, including inflammatory and neurological diseases. Currently, RIP1 kinase inhibitors have advanced into early clinical trials for evaluation in inflammatory diseases such as psoriasis, rheumatoid arthritis, and ulcerative colitis and neurological diseases such as amyotrophic lateral sclerosis and Alzheimer's disease ...